LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article: Nutritional Potential of Adzuki Bean Germplasm and Mining Nutri-Dense Accessions through Multivariate Analysis.

D, Deepika D / Padhi, Siddhant Ranjan / Gore, Padmavati G / Tripathi, Kuldeep / Katral, Ashvinkumar / Chandora, Rahul / Abhishek, G J / Kondal, Vishal / Singh, Rakesh / Bharadwaj, Rakesh / Bhatt, Kailash C / Rana, Jai Chand / Riar, Amritbir

Foods (Basel, Switzerland)

2023 Volume 12, Issue 22

Abstract: The adzuki bean ( ...

Abstract	The adzuki bean (
Language	English
Publishing date	2023-11-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2704223-6
ISSN	2304-8158
ISSN	2304-8158
DOI	10.3390/foods12224159
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.

Gore, Vishal / Kshirsagar, Dinesh P / Bhat, Shreepad M / Khatib, Khalid I / Mansukhani, Bhavna

The Journal of the Association of Physicians of India

2021 Volume 69, Issue 2, Page(s) 13–18

Abstract: Background: Hyperinflammation, hypercoagulation and multi-organ dysfunction are life-threatening complications needing immediate attention in moderate-tosevere COVID-19 patients. We present our real world experience with Itolizumab, a repurposed ... ...

Abstract	Background: Hyperinflammation, hypercoagulation and multi-organ dysfunction are life-threatening complications needing immediate attention in moderate-tosevere COVID-19 patients. We present our real world experience with Itolizumab, a repurposed immunomodulatory monoclonal antibody, administered in COVID-19 patients. Methodology: Data from 25 confirmed moderate-to-severe COVID-19 patients, with high levels of pro-inflammatory markers and pulmonary function worsening on best supportive care and Itolizumab were included in this analysis. Patients requiring invasive mechanical ventilation were excluded. Clinical parameters (oxygen requirement) and laboratory parameters (ferritin, interleukin [IL]-6, C-reactive protein [CRP] and absolute lymphocyte count [ALC]) were studied preand post-treatment. Average total length of stay in hospital and ICU, percentage of patients requiring ICU admission and average time taken for weaning off oxygen for all patients were also reported. Results: All Patients were in the range of 30-78 years of age, with majority being male (76%). Most prevalent comorbid conditions were diabetes (64%) and hypertension (28%). Median IL-6 value showed a decline by 85.4%. Significant reduction in median CRP (86.96%) and Ferritin (55.61%) was observed post- Itolizumab compared to pre-dose values. Median ALC improved from 1605 cells/ mm3 (pre-dose) to 2462.5 cells/mm3 (post-dose). Average recovery time, defined as time from Itolizumab infusion to discharge was 9.28 ± 4.04 days. Average duration of hospitalization and ICU admission was 14.24 ± 4.15 and 8.27 ± 4.47 days, respectively, with 76% patients recovered and discharged. Median oxygen saturation improved from 88 % (pre-dose) to 96 % (post-dose). All patients were weaned off oxygen within Avg + SD : 6.53 ± 2.09 days post-Itolizumab treatment. One and two point reduction in ordinal scale was observed in 88% and 76% patients, respectively. Three patients (12%) did not show improvement in ordinal sore of which two patients died because of complications due to pre-existing comorbidities. The all-cause mortality of 8%; was considered not related to Itolizumab. One infusion related event reported abated with infusion period extension. Interpretation and conclusion: A single dose of Itolizumab accelerated recovery in adult patients with COVID-19 by controlling immune hyperactivation. The clinical improvement was demonstrated by reduction in inflammatory markers, weaning off oxygen, reduced length of hospital stay and improvement of ordinal score. Itolizumab was well tolerated and when administered in the early phase of the inflammatory cascade is an efficient therapeutic option for treatment of cytokine release syndrome in moderate to severe COVID-19 patients.
MeSH term(s)	Adult ; Antibodies, Monoclonal, Humanized ; COVID-19/drug therapy ; Cytokine Release Syndrome ; Humans ; Male ; Respiratory Distress Syndrome/drug therapy ; Retrospective Studies ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; itolizumab (XQQ2RHV14N)
Language	English
Publishing date	2021-02-16
Publishing country	India
Document type	Journal Article
ZDB-ID	800766-4
ISSN	0004-5772
ISSN	0004-5772
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 313: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Endoscopic Decompression Can Be Effective for Diagnosing and Treating Tubercular Spondylodiskitis with Early Epidural Spinal Compression: A Retrospective Study of 18 Cases.

Pawar, Abhijit / Manwani, Chirag / Thete, Raghavendra / Bapat, Mihir / Peshettiwar, Vishal / Gore, Satishchandra

Asian spine journal

2018 Volume 12, Issue 5, Page(s) 803–809

Abstract: Study design: Retrospective study.: Purpose: In this study, we describe an endoscopic method of effectively treating tubercular lumbar spondylodiskitis with early onset epidural spinal cord compression in the lumbar spine on magnetic resonance ... ...

Abstract	Study design: Retrospective study. Purpose: In this study, we describe an endoscopic method of effectively treating tubercular lumbar spondylodiskitis with early onset epidural spinal cord compression in the lumbar spine on magnetic resonance imaging (MRI). Overview of literature: Percutaneous aspiration and biopsy of spondylodiskitis under ultrasonography and computer tomography scan invariably provides an inadequate diagnosis. Methods: From May 2015 to May 2017, 18 patients presented with intractable back pain and were diagnosed with tubercular spondylodiskitis on MRI; these patients were enrolled in this study. The goal was to confirm the pathogen on biopsy, drain the abscess, and perform debridement. Chemotherapy was started after histologic diagnosis, and data collected included blood cell counts, erythrocyte sedimentation rate, C-reactive protein, and repeat MRI after 3 months. Results: Mean duration of surgery was 52 minutes. Mean follow-up was 17 months. The average preoperative Visual Analog Scale score of 8 (range, 6-10) decreased to 3 (range, 1-8) postoperatively. Tubercular spondylodiskitis was observed in 14 cases; two cases were pyogenic, and the biopsy was inconclusive in two cases. After adequate chemotherapy, no recurrences were noted. Conclusions: We hereby conclude that endoscopic biopsy and drainage can provide a better diagnosis and decrease pain in a predictable manner.
Language	English
Publishing date	2018-09-10
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2559763-2
ISSN	1976-7846 ; 1976-1902
ISSN (online)	1976-7846
ISSN	1976-1902
DOI	10.31616/asj.2018.12.5.803
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6861: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endoscopic Decompression Can Be Effective for Diagnosing and Treating Tubercular Spondylodiskitis with Early Epidural Spinal Compression

Abhijit Pawar / Chirag Manwani / Raghavendra Thete / Mihir Bapat / Vishal Peshettiwar / Satishchandra Gore

Asian Spine Journal, Vol 12, Iss 5, Pp 803-

A Retrospective Study of 18 Cases

2018 Volume 809

Abstract: Study Design Retrospective study. Purpose In this study, we describe an endoscopic method of effectively treating tubercular lumbar spondylodiskitis with early onset epidural spinal cord compression in the lumbar spine on magnetic resonance imaging (MRI). ...

Abstract	Study Design Retrospective study. Purpose In this study, we describe an endoscopic method of effectively treating tubercular lumbar spondylodiskitis with early onset epidural spinal cord compression in the lumbar spine on magnetic resonance imaging (MRI). Overview of Literature Percutaneous aspiration and biopsy of spondylodiskitis under ultrasonography and computer tomography scan invariably provides an inadequate diagnosis. Methods From May 2015 to May 2017, 18 patients presented with intractable back pain and were diagnosed with tubercular spondylodiskitis on MRI; these patients were enrolled in this study. The goal was to confirm the pathogen on biopsy, drain the abscess, and perform debridement. Chemotherapy was started after histologic diagnosis, and data collected included blood cell counts, erythrocyte sedimentation rate, C-reactive protein, and repeat MRI after 3 months. Results Mean duration of surgery was 52 minutes. Mean follow-up was 17 months. The average preoperative Visual Analog Scale score of 8 (range, 6–10) decreased to 3 (range, 1–8) postoperatively. Tubercular spondylodiskitis was observed in 14 cases; two cases were pyogenic, and the biopsy was inconclusive in two cases. After adequate chemotherapy, no recurrences were noted. Conclusions We hereby conclude that endoscopic biopsy and drainage can provide a better diagnosis and decrease pain in a predictable manner.
Keywords	Tubercular spondylodiskitis ; Endoscopic debridement ; Infective spondylodiskitis ; Psoas abscess ; Biopsy ; Medicine ; R
Subject code	610
Language	English
Publishing date	2018-10-01T00:00:00Z
Publisher	Korean Spine Society
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?

Smith, Steven J / Busby, John / Heaney, Liam G / Pfeffer, Paul E / Jackson, David J / Yang, Freda / Fowler, Stephen J / Menzies-Gow, Andrew / Idris, Elfatih / Brown, Thomas / Gore, Robin / Faruqi, Shoaib / Dennison, Paddy / Dodd, James W / Doe, Simon / Mansur, Adel H / Priyadarshi, Radhika / Holmes, Joshua / Hearn, Andrew /

Al-Aqqad, Hamsa / Loewenthal, Lola / Cooper, Angela / Fox, Lauren / Selvan, Mayurun / Crooks, Michael G / Thompson, Alison / Higbee, Daniel / Fawdon, Michelle / Nathwani, Vishal / Holmes, LeanneJo / Chaudhuri, Rekha

ERJ open research

2021 Volume 7, Issue 1

Abstract: Asthma therapy, including monoclonal antibodies, was not associated with #COVID19 infection or hospitalisation in a UK severe asthma population. Shielding led to a reported worsening of mental health in nearly half of patients contacted (47%). ...

Abstract	Asthma therapy, including monoclonal antibodies, was not associated with #COVID19 infection or hospitalisation in a UK severe asthma population. Shielding led to a reported worsening of mental health in nearly half of patients contacted (47%).
Language	English
Publishing date	2021-02-01
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00768-2020
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse

Steven J. Smith / John Busby / Liam G. Heaney / Paul E. Pfeffer / David J. Jackson / Freda Yang / Stephen J. Fowler / Andrew Menzies-Gow / Elfatih Idris / Thomas Brown / Robin Gore / Shoaib Faruqi / Paddy Dennison / James W. Dodd / Simon Doe / Adel H. Mansur / Radhika Priyadarshi / Joshua Holmes / Andrew Hearn /

Hamsa Al-Aqqad / Lola Loewenthal / Angela Cooper / Lauren Fox / Mayurun Selvan / Michael G. Crooks / Alison Thompson / Daniel Higbee / Michelle Fawdon / Vishal Nathwani / LeanneJo Holmes / Rekha Chaudhuri

ERJ Open Research, Vol 7, Iss

the virus or the lockdown?

2021 Volume 1

Keywords	Medicine ; R
Language	English
Publishing date	2021-02-01T00:00:00Z
Publisher	European Respiratory Society
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Post-operative budesonide irrigations for patients with polyposis: a blinded, randomized controlled trial.

Rawal, Rounak B / Deal, Allison M / Ebert, Charles S / Dhandha, Vishal H / Mitchell, Candace A / Hang, Anna X / Gore, Mitchell R / Senior, Brent A / Zanation, Adam M

Rhinology

2015 Volume 53, Issue 3, Page(s) 227–234

Abstract: Objective: To compare normal saline (NS) vs. NS+budesonide irrigations in post- functional endoscopic sinus surgery (FESS) patients with chronic rhinosinusitis with polyposis (CRSwNP). Currently, no evidence exists for NS+budesonide irrigation over NS ... ...

Abstract	Objective: To compare normal saline (NS) vs. NS+budesonide irrigations in post- functional endoscopic sinus surgery (FESS) patients with chronic rhinosinusitis with polyposis (CRSwNP). Currently, no evidence exists for NS+budesonide irrigation over NS irrigation alone. Study design: Prospective, single-blind, randomized controlled trial. Methods: Subjects were prospectively enrolled to NS or NS+budesonide arms. Patients were evaluated at pre-operative and three post-operative visits (POV): POV1 (1-2 weeks post-op), POV2 (3-8 weeks post-op), and POV3 (3-6 months post-op). Patients were evaluated by three quality of life (QOL) questionnaires (SNOT-22, RSOM-31, and RSDI) and two olfaction scores (UPSIT and the PEA test). Results: Fifty patients were randomized, with 25 patients in the NS arm and 25 patients in the NS+budesonide arm. Two patients had unexpected pathology and were excluded from the study. By POV2 and POV3, patients experienced a significant improvement in all three QOL surveys, although the degree of improvement between arms was not significant up through POV3. Neither arm experienced significant olfactory improvement up through POV3. Conclusions: While both NS and NS+budesonide treatments improve QOL for post-FESS patients, neither intervention significantly increases QOL as compared to the other. Olfaction was not significantly improved in either treatment group.
MeSH term(s)	Adult ; Budesonide/administration & dosage ; Chronic Disease ; Female ; Glucocorticoids/administration & dosage ; Humans ; Male ; Middle Aged ; Nasal Polyps/complications ; Nasal Polyps/pathology ; Nasal Polyps/surgery ; Postoperative Care ; Prospective Studies ; Quality of Life ; Recovery of Function ; Rhinitis/complications ; Rhinitis/pathology ; Rhinitis/surgery ; Single-Blind Method ; Sinusitis/complications ; Sinusitis/pathology ; Sinusitis/surgery ; Smell ; Therapeutic Irrigation ; Treatment Outcome
Chemical Substances	Glucocorticoids ; Budesonide (51333-22-3)
Language	English
Publishing date	2015-09-10
Publishing country	Netherlands
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80336-4
ISSN	0300-0729
ISSN	0300-0729
DOI	10.4193/Rhino14.196
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1080: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.

Karnik, Niteen D / Sridharan, Kannan / Jadhav, Sonali P / Kadam, Prashant P / Naidu, Raghu K / Namjoshi, Rahul D / Gupta, Vishal / Gore, Mangesh S / Surase, Pallavi V / Mehta, Preeti R / Gogtay, Jaideep A / Thatte, Urmila M / Gogtay, Nithya J

European journal of clinical pharmacology

2013 Volume 69, Issue 7, Page(s) 1429–1436

Abstract: Purpose: Colistin, which had not been used widely because of nephrotoxicity and neurotoxicity, has gained clinical importance in recent times due to the resurgence of multidrug-resistant Gram-negative bacilli. Very few studies, especially ... ...

Abstract	Purpose: Colistin, which had not been used widely because of nephrotoxicity and neurotoxicity, has gained clinical importance in recent times due to the resurgence of multidrug-resistant Gram-negative bacilli. Very few studies, especially pharmacokinetic studies, have been performed with intravenous colistimethate sodium, and none in India. The aim of our study was to study the single-dose and steady-state pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative bacilli infections. Method: This was a prospective open-label pharmacokinetic study done in an intensive care unit in a tertiary care hospital on 15 critically ill patients with proven multidrug-resistant Gram-negative bacilli infection. Colistimethate sodium was injected as intermittent intravenous infusions in accordance with the recommendations on the package insert. For patients weighing ≥ 60 kg with a normal renal function or with a creatinine clearance (CL(CR)) of between 20 and 50 ml/min, the drug was administered at 2 million international units (MIU) every 8 h; for those with a CL(CR) of 10-20 ml/min, the dose was 2 MIU every 12 h. Those patients who weighed <60 kg were administered 50,000 IU/kg/day in three divided doses at 8-h intervals. Both single-dose and steady-state pharmacokinetics of colistin were determined and correlated with clinical outcomes. Results: A wide inter-individual variation was observed in pharmacokinetic parameters. The median (range) of the maximum plasma drug concentration/minimum inhibitory concentration (C(max)/MIC) ratio for Acinetobacter spp. was 13.4 (1.3-40.3) following the administration of a single dose of colistimethate sodium and 26.3 (0.9-64.9) at steady-state. For Pseudomonas spp., these values were 3.18 (1.6-23.1) following the single dose and 3.82 (2.3-10.9) at steady-state. For those patients whose cultures grew Acinetobacter spp., an optimum value of the C(max)/MIC ratio of >8 was achieved in seven of nine patients after the single dose and in seven of eight patients at steady-state. For those patients whose cultures grew Pseudomonas spp, only one patient after the single dose and one patient at steady-state achieved a C(max)/MIC ratio of >8. A significant association was noted between dose and survival, and a trend was observed with patients weighing ≤ 60 kg (who received 50,000 IU/kg/day instead of 6 MIU/day for those >60 kg) having an increased mortality. Conclusion: The pharmacokinetic parameters of colistin were comparable to those reported in previous studies in critically ill patients. However, the recommended dose may be inadequate to maintain the C(max)/MIC ratio to an optimal level-at least in patients infected with Pseudomonas spp. The dose recommendation should be based only on creatinine clearance and not body weight.
MeSH term(s)	Acinetobacter/classification ; Acinetobacter/drug effects ; Acinetobacter/isolation & purification ; Adolescent ; Adult ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/blood ; Anti-Bacterial Agents/pharmacokinetics ; Colistin/administration & dosage ; Colistin/adverse effects ; Colistin/analogs & derivatives ; Colistin/blood ; Colistin/pharmacokinetics ; Drug Resistance, Multiple, Bacterial ; Female ; Gram-Negative Bacterial Infections/blood ; Gram-Negative Bacterial Infections/complications ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Humans ; India ; Infusions, Intravenous ; Intensive Care Units ; Kidney/physiopathology ; Klebsiella pneumoniae/classification ; Klebsiella pneumoniae/drug effects ; Klebsiella pneumoniae/isolation & purification ; Male ; Methicillin-Resistant Staphylococcus aureus/classification ; Methicillin-Resistant Staphylococcus aureus/drug effects ; Methicillin-Resistant Staphylococcus aureus/isolation & purification ; Microbial Sensitivity Tests ; Pseudomonas/classification ; Pseudomonas/drug effects ; Pseudomonas/isolation & purification ; Renal Insufficiency/complications ; Renal Insufficiency/physiopathology ; Tertiary Care Centers ; Young Adult
Chemical Substances	Anti-Bacterial Agents ; colistinmethanesulfonic acid (DL2R53P963) ; Colistin (Z67X93HJG1)
Language	English
Publishing date	2013-03-19
Publishing country	Germany
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	121960-1
ISSN	1432-1041 ; 0031-6970
ISSN (online)	1432-1041
ISSN	0031-6970
DOI	10.1007/s00228-013-1493-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 672: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito